A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Oct 13, 2026 Trial sites expanded: 69 → 81 locations
2. Minor Sep 28, 2026 Trial sites expanded: 64 → 69 locations
3. Minor Sep 16, 2026 Trial sites expanded: 58 → 64 locations

   • Eligibility criteria expanded, about 18 words
4. Minor Sep 4, 2026 Trial sites expanded: 53 → 58 locationsv9
5. Minor Aug 21, 2026 Study sites: 51 to 53v8
6. Minor Aug 14, 2026 Trial sites expanded: 36 → 51 locationsv7
7. Minor Jul 27, 2026 Trial sites expanded: 29 → 36 locationsv6
8. Minor Jul 9, 2026 Study sites: 27 to 29

   • Primary completion date: Aug 3, 2027 to Jul 31, 2027
   • Study completion date: Jan 17, 2028 to Jan 12, 2028

   v5
9. Minor Jul 2, 2026 Trial sites expanded: 20 → 27 locations

   • Primary completion date: Jul 31, 2027 to Aug 3, 2027
   • Study completion date: Jan 12, 2028 to Jan 17, 2028

   v4
10. Minor Jun 18, 2026 Study sites: 18 to 20v3
11. Notable Jun 10, 2026 Recruitment openedv2 Show 4 more changesShow less

    • Trial sites expanded: 0 → 18 locations
    • Primary completion date: Aug 3, 2027 to Jul 31, 2027
    • Study completion date: Jan 17, 2028 to Jan 12, 2028
    • Start date changed from estimate of Jun 1, 2026 to May 27, 2026
12. Minor May 22, 2026 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.